NCT00696930撤回2 期
A Phase II Open-label Multi-center Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
研究概览
简要总结
Subjects will be screened to determine OctreoScan® uptake. And upon meeting the eligibility criteria, 90 subjects will complete a symptom assessment scale at baseline and throughout the study at specific time points. Actual treatment will consist of three six-week cycles of a fixed total dose of 13.3 GBq (360 mCi) of 90Y-SMT487. The total dose will be divided into three equal doses and administered as a single activity of 4.4 GBq (120 mCi) of 90Y-SMT487 once every six weeks for three cycles. An amino acid infusion will be administered along with each dose. Long-term follow up will occur at 6 and 12 months after Day 1/ Cycle 1. Survival will be assessed every six months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Life expectancy > 6 months.
- •Subjects must have distant metastases.
- •Subjects must be able to discontinue Sandostatin LAR treatment for at least 1 month prior to Day 1/Cycle 1; last dose of Sandostatin LAR must be 60 days or more prior to the first OctreoTher™ dose. For subcutaneous Sandostatin discontinuation should be 12 hours. Subjects taking other long acting somatostatin analogues must discontinue the analogue at least 2 times the dosing interval.
- •Upon baseline disease assessment, all subjects must have at least 1 measurable site of disease that either has never been irradiated or if the measurable lesion has been previously irradiated; this same lesion has since demonstrated progression base don the SWOG response criteria.
- •Subjects must state or agree with the statement that "I have symptoms from my cancer that bother me." Subjects must have failed to gain complete symptom control despite an optimal attempt at somatostatin therapy in the judgement of their physician.
排除标准
- •Chemotherapy, biologic therapy or other investigational therapy within 4 weeks of Day
- •Surgery, hormonal therapy (not including somatostatin analogues) or radiation, within 2 weeks of Day
- •Subjects with know brain metastases unless these metastases have been treated and stabilized for at least six months prior to study start.
- •Subjects who received high dose OctreoScan therapy or other radiolabelled somatostatin therapy or other systemic radiolabelled therapy (e.g. MIBG) for treatment of metastatic carcinoid.
研究者
相似试验
已完成
2 期
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibAdvanced Renal Cell CarcinomaNCT00853372Amgen85
Unknown
2 期
A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial VaginosisBacterial VaginosisNCT01089348Avva Rus, JSC90
招募中
1 期
A Study of HB0045 Injection in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT06056323Shanghai Huaota Biopharmaceutical Co., Ltd.71
已完成
2 期
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-StudyPTSDNCT04030169MAPS Europe B.V.21
已完成
1 期
Glyburide Advantage in Malignant Edema and Stroke PilotIschemic StrokeNCT01268683Remedy Pharmaceuticals, Inc.10